

A Survival Case of High-Dose Amlodipine Intoxication With Unusual Manifestation of Type 2 Respiratory Failure

Review began 03/11/2025
Review ended 03/16/2025
Published 03/18/2025

© Copyright 2025

Jesiah et al. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

DOI: 10.7759/cureus.80768

Nicholsan Jesiah ¹, Yathukulan Siva ¹, Pakkiyaretnam Mayurathan ^{1, 2}

¹. University Medical Unit, Teaching Hospital Batticaloa, Batticaloa, LKA ². Department of Clinical Sciences, Faculty of Health-Care Sciences, Eastern University of Sri Lanka, Batticaloa, LKA

Corresponding author: Nicholsan Jesiah, jniky915@gmail.com

Abstract

Amlodipine, a calcium channel blocker of the dihydropyridine class, is frequently used to treat high blood pressure. While overdoses are rare, they can result in significant cardiovascular compromise and, infrequently, respiratory failure. We report the case of a 17-year-old male patient who presented with an intentional amlodipine overdose, and his clinical course was complicated by type 2 (hypercapnic) respiratory failure, necessitating mechanical ventilation and intensive care management. He achieved full recovery with fluid resuscitation, calcium supplementation, high-dose insulin euglycemic therapy, vasopressor support, lung-protective ventilation, and supportive therapy. This case report highlights the importance of early detection and timely management of amlodipine toxicity, which can lead to severe complications such as cardiovascular instability, fluid overload, and respiratory distress with type 2 respiratory failure.

Categories: Cardiology, Emergency Medicine, Internal Medicine

Keywords: amlodipine, calcium channel blocker, hyperinsulinemic euglycemic therapy, toxicity, type 2 respiratory failure

Introduction

Amlodipine belongs to the dihydropyridine class of calcium channel blockers and is widely utilized in the treatment of high blood pressure and angina. Its effects are due to its selective action on L-type calcium channels in vascular smooth muscle. Overdose, though uncommon, can lead to profound hypotension, bradycardia, and, in severe cases, multiorgan dysfunction [1]. While the cardiovascular effects are well documented, complications such as respiratory failure are less frequently reported [2]. Type 2 respiratory failure (characterized by hypercapnia and alveolar hypoventilation) in the context of amlodipine toxicity may arise secondary to a combination of hemodynamic compromise, reduced respiratory drive, or secondary neuromuscular effects [3]. Early recognition and comprehensive supportive care are pivotal for a favorable outcome. Here, we present a case of amlodipine overdose in a young patient complicated by type 2 respiratory failure, successfully managed in an intensive care setting with early elective intubation.

Case Presentation

A 17-year-old boy was taken to the emergency department around four hours after intentionally ingesting approximately 60 tablets of amlodipine (5 mg each). He reported lightheadedness, nausea, and increasing shortness of breath. There was no significant past medical history, and no known allergies were reported. Initially, the patient was admitted to his local hospital, where he underwent gastric lavage, was given 50 g of activated charcoal and adequate hydration, and commenced on noradrenaline. He was later transferred to our hospital for further management.

On admission, the patient was conscious and afebrile at the resuscitation unit, with a pulse rate of 58 beats/minute, blood pressure of 90/50 mmHg, respiratory rate of 12 breaths/minute, and SpO₂ of 96% on room air. On systemic examination, bilateral fine crepitations were heard on lung auscultation. Electrocardiography revealed sinus bradycardia without conduction blocks (Figure 1). Transthoracic echocardiography showed global hypokinesia of the left ventricle with an ejection fraction of 35% (Figure 2). Chest X-ray indicated features of pulmonary edema (Figure 3), while basic laboratory tests were otherwise normal.

How to cite this article

Jesiah N, Siva Y, Mayurathan P (March 18, 2025) A Survival Case of High-Dose Amlodipine Intoxication With Unusual Manifestation of Type 2 Respiratory Failure. Cureus 17(3): e80768. DOI 10.7759/cureus.80768



FIGURE 1: Electrocardiogram shows sinus bradycardia on the rhythm strip




FIGURE 2: Transthoracic M-mode echocardiogram shows increased end-diastolic and end-systolic left ventricular diameters with global hypokinesia (HFrEF-35%)

HFrEF: Heart failure with reduced ejection fraction



FIGURE 3: Chest X-ray shows alveolar edema with "Batwing" appearance. There were Kerley B lines and peribronchial cuffing due to interstitial edema. There were upper lobe diversion of pulmonary vessels, cardiomegaly, and bilateral blunting of costophrenic angles (pleural effusion) due to heart failure

High insulin euglycemic therapy (HIET) was started with an insulin-dextrose infusion (0.5 U/kg/hour) and a 10% calcium gluconate infusion (40 ml/hour). After an hour, his blood pressure dropped to 70/45 mmHg. Doses of noradrenaline were increased, and we added a dobutamine infusion. Despite these measures, the patient's respiratory status deteriorated. The arterial blood gas analysis demonstrated worsening hypercapnia and hypoxemia consistent with type 2 respiratory failure. Because of the declining mental status and inadequate ventilation, the patient was intubated and placed on mechanical ventilation with lung-protective strategies. He was admitted to the intensive care unit, where he received continuous monitoring and supportive care. Insulin-dextrose and calcium gluconate infusions were gradually tapered off and stopped after 72 hours. On the fifth day, the patient was extubated, demonstrated complete clinical recovery, and was shifted to the ward. He was subsequently discharged on the seventh day, and outpatient follow-up, including counseling and further evaluation of his mental health, was arranged.

Discussion

Amlodipine overdose predominantly manifests with cardiovascular depression, including hypotension and bradycardia, due to excessive inhibition of L-type calcium channels [4]. However, this case highlights that a profound overdose can also disrupt respiratory function, leading to type 2 respiratory failure characterized by inadequate alveolar ventilation and resultant hypercapnia [5,6]. This may occur secondary to central nervous system depression impairing respiratory drive, hemodynamic compromise reducing cardiac output, systemic hypotension leading to respiratory muscle fatigue, metabolic derangements from HIET, and the toxin itself transiently depressing neuromuscular function [7].

The management of calcium channel blocker toxicity remains largely supportive. The early institution of HIET has been associated with improved outcomes, likely by enhancing myocardial carbohydrate utilization and improving contractility [8]. Calcium supplementation helps overcome the competitive blockade at L-type channels, while vasopressors aid in maintaining perfusion [9]. In our patient, these therapies, coupled with timely respiratory support via mechanical ventilation, were critical in reversing the toxic effects and preventing further complications. In this case, we used a continuous intravenous infusion of 10% calcium gluconate at 40 ml/hour and insulin at 0.5 U/kg/hour with a 25% dextrose infusion at 50 ml/hour.

Atropine is administered for symptomatic bradycardia. If the bradycardia is severe and does not respond to atropine or an isoprenaline infusion, transvenous pacing is considered [10]. The primary concern is hypotension, which is first treated with intravenous fluids. After ensuring adequate hydration, inotropes may be introduced. Hemodialysis is not effective because these drugs are highly protein-bound, have a large volume of distribution (21 L/kg), and undergo rapid metabolism [11].

This case is a reminder that although respiratory failure is not the most common manifestation of amlodipine toxicity, clinicians should be vigilant for signs of hypoventilation and hypercapnia. A multidisciplinary approach involving critical care, toxicology, and mental health services is essential for the comprehensive management of such patients. While managing amlodipine toxicity can be difficult, timely and intensive treatment can significantly enhance the patient's prognosis.

Conclusions

This case report highlights the successful management of a 17-year-old male patient with an amlodipine overdose complicated by type 2 respiratory failure. Early aggressive supportive care, including IV fluids, calcium supplementation, high-dose insulin euglycemic therapy, vasopressor support, and timely mechanical ventilation, was pivotal in achieving a favorable outcome. Awareness of the potential for respiratory complications resulting from a calcium channel blocker overdose can facilitate prompt diagnosis and treatment, ultimately improving patient prognosis.

Additional Information

Author Contributions

All authors have reviewed the final version to be published and agreed to be accountable for all aspects of the work.

Concept and design: Nicholsan Jesiah, Yathukulan Siva, Pakkiyaretnam Mayurathan

Acquisition, analysis, or interpretation of data: Nicholsan Jesiah, Yathukulan Siva, Pakkiyaretnam Mayurathan

Drafting of the manuscript: Nicholsan Jesiah, Yathukulan Siva, Pakkiyaretnam Mayurathan

Critical review of the manuscript for important intellectual content: Nicholsan Jesiah, Yathukulan Siva, Pakkiyaretnam Mayurathan

Supervision: Nicholsan Jesiah, Yathukulan Siva, Pakkiyaretnam Mayurathan

Disclosures

Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. **Conflicts of interest:** In compliance with the ICMJE uniform disclosure form, all authors declare the following: **Payment/services info:** All authors have declared that no financial support was received from any organization for the submitted work. **Financial relationships:** All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. **Other relationships:** All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. Kerns W 2nd: Management of beta-adrenergic blocker and calcium channel antagonist toxicity . *Emerg Med Clin North Am.* 2007, 25:309-31; abstract viii. [10.1016/j.emc.2007.02.001](https://doi.org/10.1016/j.emc.2007.02.001)
2. St-Onge M, Anseeuw K, Cantrell FL, et al.: Experts consensus recommendations for the management of calcium channel blocker poisoning in adults. *Crit Care Med.* 2017, 45:e306-15. [10.1097/CCM.0000000000002087](https://doi.org/10.1097/CCM.0000000000002087)
3. St-Onge M: Cardiovascular drug toxicity. *Crit Care Clin.* 2021, 37:563-76. [10.1016/j.ccc.2021.03.006](https://doi.org/10.1016/j.ccc.2021.03.006)
4. Vogt S, Mehlig A, Hunziker P, et al.: Survival of severe amlodipine intoxication due to medical intensive care. *Forensic Sci Int.* 2006, 161:216-20. [10.1016/j.forsciint.2006.02.051](https://doi.org/10.1016/j.forsciint.2006.02.051)
5. Hasson R, Mulcahy V, Tahir H: Amlodipine poisoning complicated with acute non-cardiogenic pulmonary

- oedema. *BMJ Case Rep.* 2011, 2011: [10.1136/bcr.07.2011.4467](https://doi.org/10.1136/bcr.07.2011.4467)
6. Humbert VH Jr, Munn NJ, Hawkins RF: Noncardiogenic pulmonary edema complicating massive diltiazem overdose. *Chest.* 1991, 99:258-9. [10.1378/chest.99.1.258](https://doi.org/10.1378/chest.99.1.258)
 7. Saravu K, Balasubramanian R: Near-fatal amlodipine poisoning. *J Assoc Physicians India.* 2004, 52:156-7.
 8. Patel NP, Pugh ME, Goldberg S, Eiger G: Hyperinsulinemic euglycemia therapy for verapamil poisoning: a review. *Am J Crit Care.* 2007, 16:498-503.
 9. Upreti V, Ratheesh VR, Dhull P, Handa A: Shock due to amlodipine overdose. *Indian J Crit Care Med.* 2013, 17:375-7. [10.4103/0972-5229.123452](https://doi.org/10.4103/0972-5229.123452)
 10. Gaudins A, Lee HM, Druda D: Calcium channel antagonist and beta-blocker overdose: antidotes and adjunct therapies. *Br J Clin Pharmacol.* 2016, 81:453-61. [10.1111/bcp.12763](https://doi.org/10.1111/bcp.12763)
 11. DeWitt CR, Waksman JC: Pharmacology, pathophysiology and management of calcium channel blocker and beta-blocker toxicity. *Toxicol Rev.* 2004, 23:223-38. [10.2165/00139709-200423040-00003](https://doi.org/10.2165/00139709-200423040-00003)